The 3‐month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis

Jasmohan S. Bajaj(Virginia Commonwealth University), Jacqueline G. O’Leary(Veterans Health Administration), Scott W. Biggins(University of Colorado Denver), Hugo E. Vargas(Mayo Clinic in Arizona), Puneeta Tandon(University of Alberta), K. Rajender Reddy(Hospital of the University of Pennsylvania), Benedict Maliakkal(University of Rochester Medical Center), Guadalupe García‐Tsao(Yale University), Michael B. Fallon(University of Arizona), Paul J. Thuluvath(University of Maryland, Baltimore), Florence Wong(University of Toronto), Patrick S. Kamath(Mayo Clinic in Arizona), Ram Subramanian(Emory University), Leroy R. Thacker(Virginia Commonwealth University)
Hepatology
December 21, 2015
10.1002/hep.28414
Cited by 237

Related Papers

Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver
|Hepatology|2014|2k
Global burden of liver disease: 2023 update
|Journal of Hepatology|2023|1.9k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Hyponatremia and Mortality among Patients on the Liver-Transplant Waiting List
|New England Journal of Medicine|2008|1.5k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k